Insider Transactions in Q2 2021 at Biomarin Pharmaceutical Inc (BMRN)
Insider Transaction List (Q2 2021)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Jun 29
2021
|
Brian Mueller EVP, Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
576
-1.84%
|
$47,808
$83.46 P/Share
|
|
Jun 21
2021
|
Jean Jacques Bienaime Director |
BUY
Exercise of conversion of derivative security
|
Direct |
1,000
+0.33%
|
$37,000
$37.46 P/Share
|
|
May 25
2021
|
Elizabeth M Anderson Director |
BUY
Grant, award, or other acquisition
|
Direct |
5,120
+26.9%
|
-
|
|
May 25
2021
|
Willard H Dere Director |
BUY
Grant, award, or other acquisition
|
Direct |
5,120
+21.76%
|
-
|
|
May 25
2021
|
Elaine J Heron Director |
BUY
Grant, award, or other acquisition
|
Direct |
5,120
+6.63%
|
-
|
|
May 25
2021
|
Maykin Ho Director |
BUY
Grant, award, or other acquisition
|
Direct |
5,120
+40.67%
|
-
|
|
May 25
2021
|
Robert J. Hombach Director |
BUY
Grant, award, or other acquisition
|
Direct |
5,120
+19.36%
|
-
|
|
May 25
2021
|
V Bryan Lawlis Director |
BUY
Grant, award, or other acquisition
|
Direct |
5,120
+17.6%
|
-
|
|
May 25
2021
|
Richard A Meier Director |
BUY
Grant, award, or other acquisition
|
Direct |
5,120
+4.9%
|
-
|
|
May 25
2021
|
David E I Pyott Director |
BUY
Grant, award, or other acquisition
|
Direct |
5,120
+12.49%
|
-
|
|
May 25
2021
|
Dennis Slamon Director |
BUY
Grant, award, or other acquisition
|
Direct |
5,120
+15.44%
|
-
|
|
May 10
2021
|
Jean Jacques Bienaime Director |
SELL
Open market or private sale
|
Direct |
8,513
-2.73%
|
$655,501
$77.29 P/Share
|
|
May 10
2021
|
Jean Jacques Bienaime Director |
BUY
Exercise of conversion of derivative security
|
Direct |
8,513
+2.65%
|
$221,338
$26.49 P/Share
|
|
May 07
2021
|
Brian Mueller EVP, Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
6,709
-17.62%
|
$530,011
$79.5 P/Share
|
|
May 07
2021
|
Brian Mueller EVP, Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
6,709
+14.98%
|
$187,852
$28.23 P/Share
|
|
May 07
2021
|
Jean Jacques Bienaime Director |
SELL
Open market or private sale
|
Direct |
25,000
-2.59%
|
$1,950,000
$78.59 P/Share
|
|
May 07
2021
|
Jean Jacques Bienaime Director |
BUY
Exercise of conversion of derivative security
|
Direct |
25,000
+7.07%
|
$650,000
$26.49 P/Share
|
|
May 06
2021
|
Jean Jacques Bienaime Director |
SELL
Open market or private sale
|
Direct |
25,000
-3.87%
|
$1,950,000
$78.35 P/Share
|
|
May 06
2021
|
Jean Jacques Bienaime Director |
BUY
Exercise of conversion of derivative security
|
Direct |
25,000
+7.07%
|
$650,000
$26.49 P/Share
|
|
May 06
2021
|
Richard A Meier Director |
SELL
Open market or private sale
|
Direct |
5,068
-5.1%
|
$395,304
$78.38 P/Share
|
|
May 06
2021
|
Richard A Meier Director |
BUY
Exercise of conversion of derivative security
|
Direct |
15,000
+13.12%
|
$390,000
$26.49 P/Share
|
|
May 04
2021
|
Charles Greg Guyer EVP, Chief Technical Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
3,986
-8.73%
|
$310,908
$78.35 P/Share
|
|
May 03
2021
|
George Eric Davis EVP, Chief Legal Officer |
SELL
Open market or private sale
|
Direct |
4,673
-3.46%
|
$364,494
$78.3 P/Share
|
|
Apr 30
2021
|
Jeffrey Robert Ajer EVP, Chief Commercial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
342
+0.58%
|
$21,204
$62.41 P/Share
|
|
Apr 30
2021
|
Andrea Acosta GVP, Chief Accounting Officer |
BUY
Grant, award, or other acquisition
|
Direct |
271
+1.45%
|
$16,802
$62.41 P/Share
|
|
Apr 30
2021
|
Brian Mueller EVP, Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
341
+1.08%
|
$21,142
$62.41 P/Share
|
|
Apr 30
2021
|
Jean Jacques Bienaime Director |
BUY
Grant, award, or other acquisition
|
Direct |
341
+0.11%
|
$21,142
$62.41 P/Share
|
|
Apr 30
2021
|
Charles Greg Guyer EVP, Chief Technical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
221
+0.48%
|
$13,702
$62.41 P/Share
|
|
Apr 30
2021
|
George Eric Davis EVP, Chief Legal Officer |
BUY
Grant, award, or other acquisition
|
Direct |
341
+0.49%
|
$21,142
$62.41 P/Share
|
|
Apr 30
2021
|
Jean Jacques Bienaime Director |
BUY
Exercise of conversion of derivative security
|
Direct |
1,000
+0.33%
|
$37,000
$37.46 P/Share
|
|
Apr 23
2021
|
Jean Jacques Bienaime Director |
SELL
Open market or private sale
|
Direct |
10,000
-3.2%
|
$790,000
$79.34 P/Share
|
|
Apr 23
2021
|
Jean Jacques Bienaime Director |
BUY
Exercise of conversion of derivative security
|
Direct |
10,000
+3.1%
|
$260,000
$26.49 P/Share
|
|
Apr 22
2021
|
Jean Jacques Bienaime Director |
SELL
Open market or private sale
|
Direct |
10,000
-3.2%
|
$780,000
$78.91 P/Share
|
|
Apr 22
2021
|
Jean Jacques Bienaime Director |
BUY
Exercise of conversion of derivative security
|
Direct |
10,000
+3.1%
|
$260,000
$26.49 P/Share
|
|
Apr 19
2021
|
George Eric Davis EVP, Chief Legal Officer |
SELL
Open market or private sale
|
Direct |
2,709
-3.81%
|
$214,011
$79.58 P/Share
|
|
Apr 19
2021
|
George Eric Davis EVP, Chief Legal Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
2,709
+3.67%
|
$70,434
$26.49 P/Share
|
|
Apr 15
2021
|
V Bryan Lawlis Director |
SELL
Open market or private sale
|
Direct |
7,500
-28.46%
|
$570,000
$76.9 P/Share
|
|
Apr 15
2021
|
V Bryan Lawlis Director |
BUY
Exercise of conversion of derivative security
|
Direct |
7,500
+22.16%
|
$195,000
$26.49 P/Share
|
|
Apr 08
2021
|
Jeffrey Robert Ajer EVP, Chief Commercial Officer |
SELL
Open market or private sale
|
Direct |
1,537
-2.57%
|
$119,886
$78.81 P/Share
|
|
Apr 01
2021
|
Brian Mueller EVP, Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
5,692
-15.51%
|
$432,592
$76.3 P/Share
|